Pejvack Motlagh

Chief Medical Officer at Mablink Bioscience

Pejvack Motlagh has extensive work experience in the pharmaceutical industry, with a focus on oncology and immunotherapy. Pejvack'smost recent role is Chief Medical Officer at Mablink Bioscience, starting in June 2023. Prior to that, they worked at Boehringer Ingelheim as the Global Head of Immuno-Oncology - TA Oncology Medicine from January 2020 to June 2023. Pejvack was also employed by AstraZeneca as the Global Clinical Lead - Global Medicines Development - Oncology R&D from July 2018 to December 2019. Pejvack served as the Disease Area Head Oncology (I-O & Hematology) / Medical EMAC at Bristol-Myers Squibb from December 2015 to July 2018. Pejvack held positions at GlaxoSmithKline, including Head of Cancer Incubator Team, Immunotherapeutics from February 2014 to December 2015, and Director, Global Early Clinical Development - Cancer Immunotherapeutics from January 2012 to February 2014. Pejvack was the Medical Director - Global Innovative Products at Teva Pharmaceuticals from January 2010 to December 2011. Pejvack also worked as a Senior Medical Advisor at Janssen Pharmaceutical companies of Johnson & Johnson, a Medical Advisor at Procter & Gamble, a Medical Manager at Caritas Internationalis, and a Medical Consultant at BearingPoint.

Pejvack Motlagh's education history began in 1988 when they enrolled at Université Paris Cité for their M.D. degree in Medical Doctor. Pejvack completed their undergraduate medical studies in 1998.

During their time at Université Paris Cité, Pejvack pursued further specialization in the field of Immunology. From 1993 to 1995, they obtained a Master of Science (M. Sc.) degree in Immunology.

Additionally, Pejvack pursued their interest in Molecular Biology at Pierre and Marie Curie University. Between 1992 and 1994, they completed a Master of Science (M. Sc.) degree in Molecular Biology.

These chronological details indicate that Pejvack Motlagh possesses comprehensive training and knowledge in the medical field, with additional expertise in Immunology and Molecular Biology gained through their academic pursuits.

Links

Timeline

  • Chief Medical Officer

    June, 2023 - present